Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Triple Negative Breast Cancer
Interventions: DRUG: PMD-026
Sponsor: Phoenix Molecular Designs